首页> 外文OA文献 >Liver transplantation for recurrent hepatocellular carcinoma on cirrhosis after liver resection: University of bologna experience
【2h】

Liver transplantation for recurrent hepatocellular carcinoma on cirrhosis after liver resection: University of bologna experience

机译:肝切除术后肝癌复发肝移植的肝移植:博洛尼亚大学的经验

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Liver resection (LR) for patients with small hepatocellular carcinoma (HCC) with preserved liver function, employing liver transplantation (LT) as a salvage procedure (SLT) in the event of HCC recurrence, is a debated strategy. From 1996 to 2005, we treated 227 cirrhotic patients with HCC transplantable: 80 LRs and 147 LTs of 293 listed for transplantation. Among 80 patients eligible for transplantation who underwent LR, 39 (49%) developed HCC recurrence and 12/39 (31%) of these patients presented HCC recurrence outside Milan criteria. Only 10 of the 39 patients underwent LT, a transplantation rate of 26% of patients with HCC recurrence. According to intention-to-treat analysis of transplantable HCC patients who underwent LR (n = 80), compared to all those listed for transplantation (n = 293), 5-year overall survival was 66% in the LR group versus 58% in patients listed for LT, respectively (p = NS); 5-year disease-free survival was 41% in the LR group versus 54% in patients listed for LT (p = NS). Comparable 5-year overall (62% vs. 73%, p = NS) and disease-free (48% vs. 71%, p = NS) survival rates were obtained for SLT and primary LT for HCC, respectively. LR is a valid treatment for small HCC and in the event of recurrence, SLT is a safe and effective procedure.
机译:对于保留了肝功能的小肝细胞癌(HCC)患者,在肝癌复发的情况下采用肝移植(LT)作为挽救程序(SLT)进行肝切除(LR)是一项有争议的策略。从1996年到2005年,我们对227例可移植的HCC肝硬化患者进行了治疗:列出了293例肝移植患者中的80例LR和147例LT。在80例接受LR移植的合格患者中,有39例(49%)发生了HCC复发,其中12/39例(31%)的患者出现了超出米兰标准的HCC复发。 39例患者中只有10例接受了LT,肝癌复发患者的移植率为26%。根据对接受LR(n = 80)的可移植HCC患者进行的意向分析,与所有列出的要移植的HCC患者(n = 293)相比,LR组的5年总生存率为66%,而LR组为58%。分别列为LT的患者(p = NS); LR组的5年无病生存率为41%,而LT组则为54%(p = NS)。肝癌的SLT和原发性LT分别获得了可比较的5年总体生存率(62%vs. 73%,p = NS)和无疾病生存率(48%vs. 71%,p = NS)。 LR是治疗小型HCC的有效方法,一旦复发,SLT是一种安全有效的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号